Viridian Therapeutics, Inc.
VRDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001590750
In the last 90 days, Viridian Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 214 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Viridian Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 128 | 1 | 124 | −3 |
| Shares | 47.1M | 1.06M | 50.2M | +4.10M (+8.9%) |
| Value | $1.12B | $25.3M | $769.9M | −$325.8M (−29.7%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (14)
Institutions that held Viridian Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Pictet Asset Management Holding SA | 1,066,343 | $16.4M | 0.02% |
| Eversept Partners, LP | 443,270 | $6.80M | 0.75% |
| Point72 Asset Management, L.P. | 439,191 | $6.74M | 0.02% |
| Twinbeech Capital LP | 94,005 | $1.44M | 0.03% |
| Polar Asset Management Partners Inc. | 76,600 | $1.18M | 0.03% |
| Davidson Kempner Capital Management LP | 23,857 | $366.0K | 0.01% |
| Dark Forest Capital Management LP | 17,223 | $264.2K | 0.02% |
| Engineers Gate Manager LP | 16,495 | $253.0K | 0.01% |
| Balyasny Asset Management LLC | 13,969 | $214.3K | 0.00% |
| Gsa Capital Partners LLP | 10,844 | $166.0K | 0.01% |
| Squarepoint Ops LLC | 10,519 | $161.4K | 0.00% |
| Orion Capital Management LLC | 200 | $3.07K | 0.00% |
| Comerica Bank | 1 | $14 | 0.00% |
| CWM, LLC | 14 | $0 | 0.00% |
Sold out (17)
Institutions that held Viridian Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Cormorant Asset Management, LP | 850,000 | $20.2M |
| Ally Bridge Group (NY) LLC | 201,752 | $4.80M |
| Woodline Partners LP | 168,060 | $4.00M |
| Fred Alger Management, LLC | 107,318 | $2.55M |
| Driehaus Capital Management LLC | 84,019 | $2.00M |
| Moody Aldrich Partners LLC | 57,451 | $1.37M |
| Algert Global LLC | 37,025 | $880.8K |
| Caption Management, LLC | 36,000 | $856.4K |
| Soleus Capital Management, L.P. | 34,000 | $808.9K |
| Two Sigma Investments, LP | 21,018 | $500.0K |
| Glenmede Trust Co NA | 13,451 | $342.2K |
| Verition Fund Management LLC | 13,300 | $316.4K |
| AQR Capital Management LLC | 12,005 | $285.6K |
| First Trust Advisors LP | 11,992 | $285.3K |
| SEI Investments Co | 9,934 | $236.3K |
| Occudo Quantitative Strategies LP | 9,720 | $231.2K |
| Aigen Investment Management, LP | 9,419 | $224.1K |
Not filed for Q3 2023 yet (1)
Institutions that held Viridian Therapeutics, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Pictet Asset Management SA | 1,061,517 | $25.3M |